It is currently Sun Jun 26, 2016 5:40 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Genomed

Dignan,

Hadn't heard of this one. I'm always wary of trial with one person. I love the bit that say's GenoMed conducts trials for free, and then charges $800 per patient per year once results have been published. What if the results say that the drug was crap and had no effect?

Ian

GenoMed Trial Results: Multiple Sclerosis - From Two Relapses a Year to None in 16 Months 23 February 2006

ST. LOUIS, GenoMed, ...
Read more : Genomed | Views : 1978 | Replies : 3


Fampridine

Does anyone know when we can expect Fampridine to be approved for MS? The person who was screening trial participants a few months ago told me that it would be later this year.
Read more : Fampridine | Views : 3890 | Replies : 7


laquinimod

From memory this drug is in human trials but they are still testing it on mice, with the usual good results.

But I think what they are trying to say is you can take it with the interferons - in other words double your money for the drugs companies (but will be packaged as more effective combination treatments).


http://www.msif.org/en/research/researc ... of_th.html
Read more : laquinimod | Views : 1664 | Replies : 0


Promising info on Symadex

Click below:

<shortened url>
Read more : Promising info on Symadex | Views : 1550 | Replies : 0


Nutra Pharma reports Preclincal

here is an important paragraph from their press release -- you can find the whole release on their site at http://www.nutrapharma.com --

The study was conducted by researchers in the Department of Anatomy and Cell Biology at the University of Saskatchewan. The lead researcher, Associate Professor Dr. Adel Mohamed, reported that the preliminary results indicate that RPI-78M inhibited the development of acute as well as the relapsing phases of ...
Read more : Nutra Pharma reports Preclincal | Views : 1956 | Replies : 3


Neurovax update

The Immune Response Corporation Announces New Business Strategy; Emphasizes Focus on Promising MS Treatment and Second Generation HIV Therapy

2/8/2006 - The Immune Response Corporation (OTCBB:IMNR) announced today that its management and the Board of Directors are implementing a new corporate and clinical strategy designed to position the Company for long-term success by more effectively leveraging its core immune-based technology for autoimmune and infectious diseases. Specifically, this strategy will focus on the accelerated development of ...
Read more : Neurovax update | Views : 1642 | Replies : 0


Update on MBP8298

Doesn't really say much about the effectiveness of the tratment

BioMS Medical's pivotal Multiple Sclerosis trial receives third positive review from Data Safety Monitoring Board 07 February 2006

EDMONTON, Feb. 7 /CNW/ - BioMS Medical Corp. a leading developer in the treatment of multiple sclerosis (MS), today announced that following the third meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical ...
Read more : Update on MBP8298 | Views : 1661 | Replies : 0


Anti-inflammatory

Only trialled on mice, may not reach the market until 5-10 years time.

But could be another move in the right direction.


Inflammatory diseases drug developed 08 February 2006

Australian scientists say they have developed a drug that may help prevent and reverse debilitating inflammatory diseases, including rheumatoid arthritis.

The new drug, developed by the Garvan Institute of Medical Research in Sydney, also could help sufferers of multiple sclerosis (MS), asthma, sepsis, heart attack ...
Read more : Anti-inflammatory | Views : 1644 | Replies : 1


Enrollment for Phase II trial of MN-166 complete

Progress...



MediciNova Announces Completion of Enrollment in a Phase II Multiple Sclerosis Trial With MN-166

Feb. 6 /PRNewswire/ -- MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced completion of enrollment of 297 patients with relapsing multiple sclerosis (MS) in its Phase II clinical trial of MN-166.

MN-166 is a novel, orally administered compound being evaluated for the treatment of ...
Read more : Enrollment for Phase II trial of MN-166 complete | Views : 1597 | Replies : 0


Hype? Rituximab

As we all know there are multitudes of drugs in trial.

Rituximab is being trialled with RR, SP and PP sufferers. Although other threads have discussed the possibility of MS being one disease with the immune system response / or not, differentiating between the various types.

The media coverage of Rituximab has been very upbeat as illustrated below:

"In patients who have been treated with rituximab and haven't responded to other treatments, Dr. Stuve says, ...
Read more : Hype? Rituximab | Views : 2315 | Replies : 3


 

Login  •  Register


Statistics

Total posts 232933 • Total topics 24943 • Total members 16082


Contact us | Terms of Service